Biodexa Pharmaceuticals Plc (BDRX) stock
BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.24−0.16 (-6.67%)
Close on Nov 16, 2026Market cap $5.06MP/E –Yield –
Biodexa Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Biodexa Pharmaceuticals's cash was £3.23M at Jun 30, 2026. For fiscal 2025 it was £8.53M, up 411.3% from the year before. Over ten years it grew -6.2% a year on average. The highest annual figure on record is £30.33M in fiscal 2014.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £8.53M | +411.3% |
| FY2024 | Dec 31, 2024 | £1.67M | -72.0% |
| FY2023 | Dec 31, 2023 | £5.97M | +110.5% |
| FY2022 | Dec 31, 2022 | £2.84M | -71.8% |
| FY2021 | Dec 31, 2021 | £10.06M | +33.3% |
| FY2020 | Dec 31, 2020 | £7.55M | -30.9% |
| FY2019 | Dec 31, 2019 | £10.93M | +366.4% |
| FY2018 | Dec 31, 2018 | £2.34M | -82.3% |
| FY2017 | Dec 31, 2017 | £13.20M | -25.0% |
| FY2016 | Dec 31, 2016 | £17.61M | +8.9% |
| FY2015 | Dec 31, 2015 | £16.18M | -46.7% |
| FY2014 | Dec 31, 2014 | £30.33M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | £3.23M | -36.1% |
| Q4 FY2025 | Dec 31, 2025 | £8.53M | +42.9% |
| Q2 FY2025 | Jun 30, 2025 | £4.04M | -22.8% |
| Q4 FY2024 | Dec 31, 2024 | £1.67M | -41.1% |
| Q2 FY2024 | Jun 30, 2024 | £5.06M | -21.3% |
| Q4 FY2023 | Dec 31, 2023 | £5.97M | -40.6% |
| Q2 FY2023 | Jun 30, 2023 | £5.23M | -30.7% |
| Q4 FY2022 | Dec 31, 2022 | £2.84M | -74.0% |
| Q2 FY2022 | Jun 30, 2022 | £6.42M | +174.1% |
| Q4 FY2021 | Dec 31, 2021 | £10.06M | -23.8% |
| Q4 FY2020 | Dec 31, 2020 | £7.55M | -57.1% |
| Q4 FY2019 | Dec 31, 2019 | £10.93M | -32.4% |
| Q4 FY2018 | Dec 31, 2018 | £2.34M | -92.3% |
| Q4 FY2017 | Dec 31, 2017 | £13.20M | – |
| Q4 FY2016 | Dec 31, 2016 | £17.61M | – |
| Q4 FY2015 | Dec 31, 2015 | £16.18M | – |
| Q4 FY2014 | Dec 31, 2014 | £30.33M | – |
See a number that looks wrong?